Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study
- Publication date
- 1 January 2021
- Publisher
- 'Springer Science and Business Media LLC'